Skip to content
drillr.ai

EW

Edwards Lifesciences Corporation

NYSE · USHealthcareMedical - Devices
$85.00-0.85%

Price as of Jul 20, 2026

EW news

Edwards Lifesciences Corporation news

A server-rendered, paginated timeline of the latest available company news.

  1. Edwards Lifesciences to Host Earnings Conference Call on July 23, 2026

    Edwards Lifesciences to Host Earnings Conference Call on July 23, 2026 Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2026 after the market closes on Thursday July 23, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at i

    Business Wire ·

  2. Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders?

    Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, July 3, 2026 Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YOR

    PR Newswire ·

  3. Edwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves

    Edwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which reinforce the company's leadership in advancing high-quality scientific evidence and innovating for patients. These new data – spanning aortic, mitral and tricuspid therapies – provide further understanding of t

    Business Wire ·

  4. Edwards Lifesciences Announces Appointment of CFO

    Edwards Lifesciences Announces Appointment of CFO Edwards Lifesciences (NYSE: EW) today announced the appointment of Theodora (“Doretta”) Mistras as the company’s corporate vice president and chief financial officer (CFO), effective at the end of May. Mistras will succeed Scott Ullem, who announced in October his planned transition from the CFO role. Mistras joins Edwards from Viatris, where she has served as CFO since March 2024, leading the company’s global finance organization and overseein

    Business Wire ·

  5. Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences’ Resilia Tissue

    Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences’ Resilia Tissue Edwards Lifesciences (NYSE: EW) today announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its proprietary RESILIA tissue. The data were presented at the 106th American Association for Thoracic Surgery Annual Meeting. As evidence increasingly supports treating patients earlier in the valve disease pathway, the need for durable val

    Business Wire ·

  6. Edwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference

    Edwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026. Bernard Zovighian, chief executive officer, will participate in a fireside chat at 3:40 p.m. Pacific Time. A live webcast of the discussion will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com (https://cts.businesswire.com/ct

    Business Wire ·

  7. Edwards Lifesciences Reports First Quarter Results

    Edwards Lifesciences Reports First Quarter Results Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2026. Highlights and Outlook * Q1 sales grew 16.7% to $1.65 billion(1), constant currency(2) sales grew 12.7% * Q1 TAVR sales grew 14.4% to $1.20 billion(1); constant currency(2) sales grew 11.0% * Q1 TMTT sales of $173 million(1,3), driven by repair and replacement therapies * Q1 EPS of $0.66(1); adjusted(2) EPS of $0.78(1) * Raising FY

    Business Wire ·

  8. Edwards Lifesciences to Host Earnings Conference Call on April 23, 2026

    Edwards Lifesciences to Host Earnings Conference Call on April 23, 2026 Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2026 after the market closes on Thursday April 23, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website a

    Business Wire ·

  9. Two Year Data on Edwards Lifesciences’ EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits

    Two Year Data on Edwards Lifesciences’ EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits TRISCEND II randomized trial data presented at ACC show lower mortality with EVOQUE system, when accounting for patient crossover Edwards Lifesciences (NYSE: EW) today announced new data on the EVOQUE transcatheter tricuspid valve replacement (TTVR) system at the American College of Cardiology Annual Scientific Session (ACC.26), demonstrating significant and sustained patient b

    Business Wire ·

  10. Edwards Lifesciences Advances Structural Heart Care Through Innovation and Purpose

    For best results when printing this announcement, please click on link below: https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260226:nBw7lPk4ga&default-theme=true Edwards Lifesciences Advances Structural Heart Care Through Innovation and Purpose At the close of Heart Month, Edwards Lifesciences (NYSE: EW) underscored its leadership in structural heart innovation, advancing care through deep expertise and strong partnerships so people with structural heart diseas

    Business Wire ·